CGM for Healthy People: Useful N=1 Toy, or Marketing in a Sticker?

A CGM does not measure your blood sugar. It is a tiny thread sensor in the fat under your upper-arm skin that reads glucose in the interstitial fluid (the watery space between your cells) and estimates your blood value from there. That fluid runs 5 to 15 minutes behind, and a typical MARD of 8 to 14 percent means any single reading carries roughly ± 10 mg/dL of real-world wobble. Here is the first thing nobody tells you in full.

It is a tiny thread sensor that sits in the fat tissue just under the skin of your upper arm. What it actually reads is glucose in the interstitial fluid (the watery space between your cells), then it estimates your blood value from there.

That fluid runs about 5 to 15 minutes behind your actual blood, and even further behind when your sugar is rising or dropping fast. So a CGM curve can look quite different from a finger-prick taken in the very same second. The sensor is not wrong. It is just reading a slightly delayed version of the story.

How accurate is it? Researchers report this as MARD, which is basically the average percentage by which the sensor misses the lab value (lower is better). A 2024 head-to-head test put two sensors on 56 adults with diabetes (33 with type 1, 23 with type 2) and checked them against a lab reference. The FreeStyle Libre 3 came in at 8.9 percent, the Dexcom G7 at 13.6 percent ^[7]. In healthy people with normal glucose the accuracy may differ. The companies' own approval trials report different figures, often closer to 8 to 9 percent for both, because who you test, how you check, and which glucose range you look at all change the result.

What this means in your hand: a reading of 95 mg/dL could really be anywhere from 86 to 104 mg/dL in your actual blood. Stick two sensors on the same arm and they will disagree, sometimes by 15 mg/dL. That is the technology working as designed, not a broken sensor.

Which devices show up in DACH? Abbott FreeStyle Libre 3, Dexcom G7, and Dexcom ONE+ are all CE-marked and mostly prescribed for diabetes. On the consumer side you have Abbott Lingo (launched in the UK and US in 2024) and Dexcom Stelo (US 2024, still rolling out across Europe). Platforms like Hello Inside, an Austrian start-up from Vienna, pair someone else's sensor with their own coaching app.

Short version: a healthy adult sits around 99 mg/dL on average, with quick little bumps to 130 to 140 mg/dL after meals. That number is not a guess. It comes from a 2019 study in the Journal of Clinical Endocrinology and Metabolism, where researchers stuck CGMs on 153 adults without diabetes across several US sites and tracked their glucose around the clock for days ^[3]. Here is what they saw:

• Average glucose over 24 hours: 99 ± 7 mg/dL.
• Time spent between 70 and 140 mg/dL: a median of 96 percent (the middle half of people landed between 93 and 98 percent).
• Time above 180 mg/dL: basically none.

People aged 60 and over spent noticeably more time above 140 mg/dL than younger adults. But even healthy young people crossed 140 now and then, almost always just briefly after a meal.

A bigger 2025 community study in the same journal told the same story. It followed a much larger group of adults without diabetes (560 of them with normal glucose) and the picture barely changed ^[10]. Average time in range (70 to 180 mg/dL) was 97.8 percent (SD 4.9). Time above 180 mg/dL was negligible for most. The real spread is tighter than the commercial CGM apps like to imply.

Here is the nuance though. Time above 180 mg/dL is uncommon, but it is not zero. About 20 percent of these normal-glucose adults still spent more than 2 percent of the day above 180 mg/dL. And in the tighter window, 70 to 140 mg/dL, the median time was about 87 percent.

Now the paper everyone quotes online: a 2018 PLOS Biology study that gave us the word "glucotypes". A Stanford team ran CGMs and fed standardized test meals to 57 adults ^[2]. Eat the exact same meal, and people's glucose responses still varied wildly. Three clear patterns showed up (low, moderate, and severe swings), even in people whose HbA1c (a three-month average blood-sugar marker) was completely normal. This is where the popular line "everyone responds differently to food" actually comes from. The claim is true, and the data are genuinely interesting. They also come from a 57-person observational study with no longevity or heart outcomes attached to it.

What about official targets? The ATTD international consensus from 2019 in Diabetes Care sets clinical CGM targets, but only for people who have diabetes ^[1]. For healthy adults, nobody has agreed on what "time in range" should even mean or whether it matters. The ADA Standards of Care 2025 (Section 7) only recommend over-the-counter CGMs for people with prediabetes or diabetes who are not on insulin. They do not back CGM as a routine wellness or longevity tool for healthy people ^[4]. The 2026 update finally acknowledges that people without diabetes also buy these biosensors to watch how their glucose reacts to their lifestyle, but it still does not make a clinical recommendation for healthy users ^[5].

In two weeks a CGM can show you three real things: how specific meals move your own curve, what a bad night of sleep does to your fasting glucose the next morning, and how alcohol, stress, illness, and exercise shift your line. It cannot diagnose anything, prove a spike is harmful, or predict your 20-year heart risk. Treat the two weeks as a one-person experiment, not a verdict.

A CGM can genuinely teach you a few things about your own body. The obvious one is how different meals move your own curve. White bread on its own versus the same bread after a walk, or eaten alongside some protein and fat, will give you different rises. That is your data, not a population average. You can also watch what a bad night of sleep does to your fasting glucose and tolerance the next morning. A 2024 narrative review (a careful summary of the existing studies) called that one of the more reliably repeatable findings from consumer CGM use ^[6]. And you can see exactly what alcohol, a cold, stress, and a hard workout do to your line.

The list of things a CGM cannot tell you is much longer. It cannot diagnose prediabetes or diabetes. Those need a fasting glucose test, an OGTT (a standard test where you drink sugar and they measure how fast you clear it), and an HbA1c, not a bunch of CGM peaks. It cannot tell you a spike to 150 mg/dL is bad. It cannot tell you whether your spike pattern predicts heart disease or death 20 years from now, because no randomized trial in healthy adults has ever asked that question. And it definitely cannot tell you to go low-carb, keto, carnivore, or start intermittent fasting. Those are clinical calls, and they belong with a Hausarzt (your GP) or a registered dietitian.

The most honest way to think about it: a CGM is a structured experiment on a single person, you. Use it to spot patterns and bring the weird ones to a doctor, and it can be useful. Treat it like a daily report card, and it tends to hand you anxiety, food avoidance, and overcorrection that is its own kind of unhealthy.

Right at the point where it claims to improve health. No randomized trial in healthy adults shows that wearing a CGM lowers heart risk or extends life, yet brands stretch a real finding (your post-meal response varies person to person) into longevity claims. The 2024 FDA clearance of over-the-counter consumer CGMs is a permission to sell, not proof of benefit. The CGM-for-wellness market is a classic case: a strong signal pulling a much weaker outcome story behind it. Abbott (Lingo), Dexcom (Stelo), Levels Health (US only, not available in DACH), NutriSense (US), Zoe (UK, which uses CGM as one input in its nutrition program), Hello Inside (Austria), Veri (Finland), Glucura and Una Health (Germany) all start from something real. Your glucose response after a meal really does vary from person to person and from food to food. Then they stretch that into claims about metabolic health and longevity that the evidence just does not back yet.

In 2024 the FDA cleared the first two over-the-counter consumer CGMs: Dexcom Stelo in March and Abbott Lingo later that year. Both sell without a prescription to adults 18 and up who are not on insulin. But that is a permission slip, not proof. It means the devices are safe enough to sell off the shelf, not that wearing one makes a healthy person healthier.

A 2024 narrative review in Diabetic Medicine looked specifically at people without diabetes wearing CGMs and came back cautious. In plain terms: the evidence that it helps is thin and all over the place, some commercial claims risk misleading people, and side effects like cutting out too many foods and getting anxious deserve real attention. The authors went so far as to call for stricter rules on consumer marketing ^[6]. A 2021 review in BMJ Open Diabetes Research and Care lands in the same spot. Swings in glucose do track with heart outcomes in type 2 diabetes, but stretching that finding onto healthy adults is not justified ^[9].

The downsides are not zero. The anchoring effect is real: someone sees a 145 mg/dL spike after porridge, panics, switches to bacon and eggs, and never questions the assumption again. The orthorexia risk is real too, where the obsession with "clean" eating becomes the problem. Case reports link CGM use to disordered eating in people who were already anxious. And the cost adds up fast. A healthy self-payer in DACH spends roughly EUR 50 to 150 per 14-day sensor at an Apotheke (pharmacy). Wear one nonstop and that is about EUR 700 to 1500 a year. None of it gets reimbursed by statutory (GKV) or private insurance without a coded diabetes diagnosis under ICD-10 E10 or E11.

Honest summary: in a healthy person, a CGM is an interesting biomarker, not a proven longevity intervention. Treat it like a sauna habit you are trying out. Use it, see if it actually changes anything you care about, then decide whether EUR 1000 a year buys you more than a single private blood panel with HbA1c, fasting insulin, and an OGTT.

Yes, but only as a self-payer. In DACH 2026 a healthy adult cannot get a CGM reimbursed and cannot reliably buy the consumer devices (Lingo, Stelo) either. The realistic path is buying prescription FreeStyle Libre 3 sensors over the counter at an Apotheke (pharmacy) for roughly EUR 50 to 75 per 14-day sensor, with no statutory or private insurance covering it. The DACH CGM scene in mid-2026 is a moving target, so check what is actually available the day you go to buy. Here is the neutral lay of the land.

Abbott FreeStyle Libre 3 is the king of prescription CGMs in Germany and Austria. It sits on the Hilfsmittelverzeichnis (the official list of reimbursable medical aids), and statutory health insurance pays for it only if you have a coded diabetes diagnosis on intensive insulin therapy or something comparable. No diagnosis? You can still buy sensors privately at an Apotheke (pharmacy) as a Selbstzahler (self-payer), at roughly EUR 50 to 75 per 14-day sensor. In Switzerland, the basic insurance (Grundversicherung) covers CGM through KLV/MiGeL only for diagnosed diabetes that meets specific clinical criteria. Wellness use by healthy people is not covered.

Abbott Lingo is the consumer version. It launched over the counter in the United Kingdom and United States in 2024 and officially only available in those two markets as of May 2026. There is no official DACH or wider EU rollout. Calling its DACH availability "patchy" is being generous. Anyone in DACH using Lingo got it through a cross-border parcel or a US/UK reshipper, because there is no CE-MDR route to sell it directly to consumers in DE, AT, or CH.

Dexcom G7 is prescription-only in DACH and meant for managing diabetes. Dexcom Stelo, the US over-the-counter product from 2024, still had not seen a full DACH consumer launch as of mid-2026. Check the maker's regional pages for the current status.

Hello Inside is a Vienna-based start-up selling a CGM-plus-coaching subscription, aimed mostly at women interested in metabolic health. The sensor underneath is a third-party Abbott device. Hello Inside is the coaching layer on top. Whether that subscription is worth paying on top of the sensor depends on how much you value the app's hand-holding. We mention it neutrally, not as a recommendation.

One thing people mix up constantly: the DiGA-approved digital health apps in Germany (Una Health, Glucura) are reimbursed for diagnosed type-2 diabetes, not for healthy users. Do not assume that coverage carries over to wellness use.

So for a healthy adult in DACH 2026, the realistic self-payer path looks like this: buy two Libre 3 sensors at an Apotheke (about EUR 100 to 150 for a month), use the maker's free app, and add a coaching service if you want one. No reimbursement applies.

The research validates blood markers, not CGM curves. For metabolism the proven set is fasting glucose, HbA1c, fasting insulin with HOMA-IR, and a 75 g OGTT; for heart and longevity it is ApoB, Lp(a), triglycerides, hs-CRP, and HDL-C. A once-a-year private panel covering these costs EUR 150 to 350 in DACH, a fraction of a year of CGM sensors, and every marker has decades of trial evidence behind it. If what you actually want is an evidence-based metabolic check-in, the proven markers are boring, cheap, and very well studied. Fasting glucose plus HbA1c gives you a reliable read on your average blood sugar over the past 8 to 12 weeks. Fasting insulin, and the HOMA-IR score you calculate from it (a simple math formula that estimates insulin resistance), is the best non-invasive stand-in for insulin resistance your Hausarzt (GP) can order. And a 75 g OGTT, where you drink a fixed sugar load and they measure glucose and insulin at 0, 60, and 120 minutes, is still the best test we have for catching impaired glucose handling and early high insulin before your HbA1c even budges.

For heart and longevity-adjacent markers, the proven set is short: ApoB and Lp(a) (a count of harmful cholesterol particles, plus a once-in-a-lifetime genetic risk marker), triglycerides, hs-CRP (a sensitive inflammation marker), and HDL-C. Pair those with blood pressure, waist size, and resting heart rate, and you have decades of randomized-trial evidence behind every one. Glucose swings from a CGM have none of that evidence in healthy adults.

Let us make it concrete. In DACH 2026, a private self-payer blood panel with HbA1c, fasting glucose, fasting insulin, a lipid panel including ApoB, hs-CRP, and basic thyroid markers costs EUR 150 to 350, once a year. A year of CGM sensors as a healthy self-payer costs EUR 700 to 1500. The blood panel has decades of outcome data behind it. The CGM has the Stanford glucotypes paper ^[2] and a healthy-cohort baseline of 153 people ^[3]. Both can be useful. Only one is actually validated.

The sensible move for a curious, longevity-minded adult: one structured two-week experiment to see what your own meals and habits do to your curve, knowing the result is data, not destiny. Then go back to the proven markers and a doctor who actually reads them, and check first what your health insurance already covers before paying out of pocket.